Gather people who had the same kind of lung cancer and put them on the same type of treatments to fire up their immune systems. The only difference was that half the group got their medications ...

The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's ...

'Highly encouraging' results uncovered after immunochemotherapy administered at different times in two groups of patients ...

Zenocutuzumab--zbco, marketed as BIZENGRI (R), received Breakthrough Therapy Designation from the FDA in October 2025 and was granted accelerated approval in December 2024 for adults with advanced ...

Evogene Ltd. (Nasdaq/TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, and ...

A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...

Comprehensive biomarker testing is crucial for NSCLC treatment, yet disparities exist between academic and community settings ...

Research reveals the efficacy of cancer therapies and organ transplant treatments may improve by synchronizing with the ...

Some cancer therapies may be more effective when given earlier in the day, aligning treatment with the body's natural rhythms ...

Nucleai, a leader in AI-powered multimodal spatial biology, today announced its contribution to a collaborative international study published in Nature Communications that explores how spatial ...

University of Queensland researchers who mapped cancer cell "neighborhoods" in the most common type of lung cancer have found ...

A new study suggests that giving lung cancer treatment in the morning could help patients live longer and slow down the growth of their cancer. The research looked at people with advanced lung cancer ...